Abstract |
Cancer cells predominantly generate energy via glycolysis, even in the presence of oxygen, to support abnormal cell proliferation. Suppression of PDHA1 by PDK1 prevents the conversion of cytoplasmic pyruvate into Acetyl-CoA. Several PDK inhibitors have been identified, but their clinical applications have not been successful for unclear reasons. In this study, endogenous PDHA1 in A549 cells was silenced by the CRISPR/Cas9 system, and PDHA1WT and PDHA13SD were transduced. Since PDHA13SD cannot be phosphorylated by PDKs, it was used to evaluate the specific activity of PDK inhibitors. This study highlights that PDHA1WT and PDHA13SD A549 cells can be used as a cell-based PDK inhibitor-distinction system to examine the relationship between PDH activity and cell death by established PDK inhibitors. Leelamine, huzhangoside A and otobaphenol induced PDH activity-dependent apoptosis, whereas AZD7545, VER-246608 and DCA effectively enhanced PDHA1 activity but little toxic to cancer cells. Furthermore, the activity of phosphomimetic PDHA1 revealed the complexity of its regulation, which requires further in-depth investigation. [BMB Reports 2021; 54(11): 563-568].
|
Authors | Ling Jin, Minkyoung Cho, Bo-Sung Kim, Jung Ho Han, Sungmi Park, In-Kyu Lee, Dongryeol Ryu, Jae Ho Kim, Sung-Jin Bae, Ki-Tae Ha |
Journal | BMB reports
(BMB Rep)
Vol. 54
Issue 11
Pg. 563-568
(Nov 2021)
ISSN: 1976-670X [Electronic] Korea (South) |
PMID | 34488935
(Publication Type: Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Pyruvate Dehydrogenase (Lipoamide)
- pyruvate dehydrogenase E1alpha subunit
|
Topics |
- A549 Cells
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
(drug therapy, enzymology, pathology)
- Drug Evaluation
(methods)
- Enzyme Inhibitors
(chemistry, pharmacology)
- Humans
- Lung Neoplasms
(drug therapy, enzymology, pathology)
- Phosphorylation
- Pyruvate Dehydrogenase (Lipoamide)
(antagonists & inhibitors)
|